RESEARCH ARTICLE

DIAGNOSTIC, THERAPEUTIC AND EVOLUTIONARY CHARACTERISTICS OF NASOPHARYNGEAL CANCER MANAGED WITH VMAT IN DEPARTMENT OF RADIOTHERAPY, MOHAMED V MILITARY TEACHING HOSPITAL - RABAT IN MOROCCO

Khalid Hadadi1, Mohcine Hommadi2, Abdelhak Maghous1, Maroa Belemlih1, Noha Zagba1, El-Amin Marnouch1, Khalid Andaloussi Saghir1, Mohamed Elmarjany1, Hassan Sifat1 and Hamid Mansouri1
1. Service De Radiothérapie, Hôpital Militaire D’instruction Mohammed - V, Université Mohammed V, Rabat, Maroc.
2. Service De Radiothérapie, Institut National D’oncologie, Rabat, Maroc.

Purpose: The aim of this study was to report the experience of Military Teaching Hospital Mohamed V (MTHM V) in the management of NPC treated with volumetric modulated arc therapy (VMAT)

Materials and Methods: This is a retrospective study conducted between January 2013 and December 2017. All patients with a nasopharyngeal cancer were included. Patients who had distant metastasis at the time of diagnosis were excluded. The volumetric arc therapy modulation of intensity (VMAT) is the technique radiotherapy used in all our patients.

Results: one hundred and one (101) patients with nasopharyngeal cancer were treated in our department. The average age was 42.95±16.36. The predominant histological type is undifferentiated carcinoma (UCNT) in 93 % of cases. Tumors were classified according to the American Joint Committee on Cancer (AJCC) classification of 2010 in Stage I : 1%, Stage II in 10.9%, Stage III in 45.5%, Stage IVa in 32.7% and stage IVb in 9.9%. The treatment consisted of neoadjuvant chemotherapy followed by concomitant radio chemotherapy (RCC) at 79.2 % of patients, an RCC immediately in 12.8 % of cases and 8 % of patients received neoadjuvant chemotherapy followed by exclusive radiotherapy. The therapeutic tolerance was good with 16.8% of acute radiomucite Grade 3, 8.9% of acute dermatitis Grade 3 and no complication Grade 4. The overall survival was 98.8% and 84.8% at 2 and 5 years respectively, and the PFS was 85.6% and 76.8% at 2 and 5 years, respectively. N3 and time to relapse were significant in multivariate analysis for OS. Neoadjuvant chemotherapy and N3 were significant in multivariate analysis for PFS.

Conclusion: volumetric modulated arc therapy with concurrent chemoradiotherapy with additional neoadjuvant chemotherapy has good response and outcomes. Our findings are in good accordance with other series but further large studies are warranted to improve prognostic of this potentially curable malignancy.

Corresponding Author:- Khalid Hadadi
Address:- Service de radiothérapie, hôpital militaire d’instruction Mohammed-V, Rabat, Maroc.
Introduction:-
Nasopharyngeal carcinoma (NPC) is the predominant tumor type arising in the nasopharynx. It differs from other head and neck squamous cell carcinomas in epidemiology, histology, natural history, and response to treatment.

Worldwide, there are around 86,000 incident cases and 50,000 deaths annually [1-3]. NPC displays a distinct racial and geographic distribution, which is reflective of its multifactorial etiology [1]. The incidence of nasopharyngeal carcinoma demonstrates a marked geographical variation. It is rare in the United States and Western Europe, with an incidence of 0.5 to 2 cases per 100,000 [2, 4]. By contrast, nasopharyngeal carcinoma is endemic in Southern China, including Hong Kong, where the incidence may reach 25 cases per 100,000 per year. Intermediate-risk regions include Southeast Asia, North Africa and the Middle East, and the Arctic. Populations that migrate from areas of high to low risk retain an elevated risk, although this risk typically diminishes in successive generations [4]. The major etiological factors for endemic nasopharyngeal carcinoma are genetic susceptibility, early-age exposure to chemical carcinogens, and Epstein-Barr virus (EBV) infection.

NPC has very good response to radiation and cure is promise, especially if early detected. Radiotherapy is the backbone treatment strategy for NPC. But about 70% of the patients with NPC present with stages III or IV are at risk to suffer from local or/regional recurrence or distant metastases after radiotherapy [5]. However, the treatment of advanced NPC often requires a combination of chemotherapy and radiation therapy. The National Comprehensive Cancer Network and European Society for Medical Oncology recommend concurrent chemoradiotherapy with or without adjuvant chemotherapy (AC) as the standard basic treatment for stage II–IVB patients. However, AC is mainly used in patients with residual disease or those with advanced disease due to the lower compliance rate, especially after concurrent chemoradiotherapy. Interestingly, neoadjuvant chemotherapy plus concurrent chemoradiotherapy has been commonly used in stage II–IVB NPC patients in many centers because the considerable response rate is high. Nevertheless, this combined treatment was recommended as level 3 evidence in the latest version of guidelines [6]. A pooled data analysis of two-Phase III studies has shown that the addition of neoadjuvant chemotherapy to RT significantly improves the disease-specific survival of stage II–IVB NPC patients but that no improvement in overall survival (OS) is observed [7].

The intensity modulated radiotherapy (IMRT) of head and neck cancer has been demonstrated often to produce greater dose distributions in terms of improved tumor exposure and lower doses to normal tissues. Three randomized trials have compared IMRT to conventional radiotherapy in the treatment of NPC [8]. Although local control rates with IMRT have improved with the advent and widespread adoption of IMRT.

The aim of this study was to report the experience of Military Hospital Teaching Mohamed V in the management of NPC treated with volumetric modulated arc therapy (VMAT)

Materials and Methods:-
This is a retrospective study spread over 5 years, conducted within radiotherapy department of the MTHM V in Rabat between January 2013 and December 2017. All data was collected via the records patient clinics. These data were then examined, coded and entered into an electronic database and validated by the study's principal investigator.

All patients benefited from a pre-therapeutic assessment including a physical examination, biochemical and hematologic assessments, a biopsy-proven fiber optic nasopharyngoscopy and histological evidence, combined with a nasopharyngeal and neck CT scan with or without MRI to assess the loco regional extension of the disease. Patients with locally advanced disease at the time of presentation received additional extension assessment including thoraco-abdominal CT scan and bone scintigraphy. Patients who had distant metastasis at the time of diagnosis were excluded. The seventh edition of the system of classification of the American Joint Committee on Cancer (AJCC) has been used for staging the diseases.

The VMAT is the technique radiotherapy used in all our patients. The simulation scanner is made with a 5-point mask, the Contouring target volumes is performed on a CT scan injected after registration on the diagnostic MRI. The nasopharyngeal gross tumor volume (GTV NP) and the neck lymph nodes (GTV NN) were
determined from the results of imaging, clinical and endoscopic. The high-risk CTV (CTV HR) covers the GTV NP and the GTV GG with a margin of 5-10mm while excluding the non-infiltrated anatomical barriers, the intermediate risk CTV NP (CTV IR NP) covers the CTV HR NP plus a margin of 5mm while including areas at risk of microscopy. The CTV GG Intermediate (CTV GG IR) covers CTV GG HR plus the nodal regions of the level II, III, IVa and back pharyngeal necks as well as the underlying and overlying levels of the levels reached. A third node level at low risk (LR) may be added including the remaining neck levels. A further 3 to 5mm margin is added to target volumes to form the PTV.

The radiotherapy was administered with a VMAT technique in simultaneous integrated boost (SIB) moderately accelerated using 2 to 3 arcs with 3 levels of high risk dose (HR) receiving 69.96 Gy, intermediate risk (IR ) : 59.4 Gy and low risk (LR) : 54 Gy , with 5 fractions per week in 33 sessions . The treatment plan is validated by the radiation oncologist and the medical physicist; priority is given to critical neurological structures, followed by target tumor volumes and organs of intermediate importance. Radiation therapy has been used alone or in combination with weekly cisplatin chemotherapy. Induction chemotherapy was administered to patients with locally advanced disease and different regimens were used based on cisplatin, anthracycline and 5-FU.

The biological monitoring and clinical courses of treatment patients had weekly for treating acute complications that may arise and ensure good compliance to treatment.

A near the end of the treatment the monitoring continued on schedule following: every 3 months for the first 2 years, every 6 months the 3rd, 4th and 5th year, then annually , it included a physical examination, particularly of the head and the neck . A nasofibroscopy and head and neck MRI were performed periodically to evaluate response, detect relapses and documenting the late complications.

The data in our series were collected using a well-structured checklist containing the important parameters of the study. Data collection included patient data (age at diagnosis and sex). The data also included clinical presenting symptoms (rhinological, otological, neurological and lymph node), duration of symptoms (months) and other clinical data such as TNM classification and stage of illness according to the seventh edition of the AJCC 2010 and histological type according to the classification of the World health Organization, the primary treatment modalities (radiotherapy, chemotherapy, both), and the complications during the treatment, and monitoring data: the time of the last consultation, the date and site of relapse (local, loco regional or distant) and date of death.

The acute and late toxicities of radiotherapy were classified according to common endpoint criteria for adverse reactions (CTCAE Version 3.0). Only grade 3 or higher toxicities have been recorded and reported.

Statistical analysis of the data was performed by SPSS 23 for MAC (SPSS, Inc., Chicago, IL, USA). The overall survival rate (OS) and survival without relapse (PFS), has been calculated and analyzed with the Kaplan-Meier method. OS was calculated from the date of histological diagnosis to the date of the last visit or death and PFS was calculated from the date of histological diagnosis to the date of the last visit or date of loco regional or distance relapse.

Results:-

During the period of the study spread over 5 years, 101 patients with nasopharyngeal cancer were treated in the radiotherapy department in the MTHM V by the VMAT type radiotherapy. The average age was 42.95±16.36; the sex ratio was 2.6 with a male predominance. The average consultation time was 6 months (4-12). The revealing signs were lymph node in 61.4%, otological in 52.5 %, rhinologic in 48.5 % and neurologic in 37.6 %. The predominant histological type is undifferentiated carcinoma (UCNT) in 93 % of cases. Tumors were classified according to the American Joint Committee on Cancer (AJCC) classification of 2010 in Stage I : 1%, Stage II in 10.9%, Stage III in 45.5%, Stage IVa in 32.7% and stage IVb in 9.9% , The distribution according to the T was as follows: T1: 12.9%, T2: 31.7%, T3: 18.8%, T4: 36.6% and the status lymph node was N0: 11.9%, N1: 22.8%, N2: 55.4%, N3 : 9.9%.

The treatment was referred curative in all patients; it consisted of neoadjuvant chemotherapy followed by concomitant chemoradiotherapy (RCC) at 79.2 % of patients, an RCC immediately in 12. 8 % of cases and 8 % of patients received neoadjuvant chemotherapy followed by exclusive radiotherapy (Table 1).
The therapeutic tolerance was good with 16.8% of acute radiomucite Grade 3, 8.9% of acute dermatitis Grade 3 and no complication Grade 4. Late complications were as following: skin fibrosis in 12.9%, lockjaw in 6.9%, Grade 3 hyposialia in 19.8%, and asialia in 2% of cases, hearing lose were found in 15.8% of patients (Table 2).

With a median follow-up of 45.37 ± 17.31 months, 3% of patients were lost sight of, the overall survival was 98.8% and 84.8% at 2 and 5 years respectively. The mean Time to relapse was 22.6 ± 10.3 months, and the PFS was 85.6% and 76.8% at 2 and 5 years, respectively (Table 3 and Fig 1, 2, 3, 4).

Different prognostic factors were included in a univariate and multivariate analysis (table 4, 5, 6). For OS: relapse delay was significant in univariate analysis, and N3 and time to relapse were significant in multivariate analysis. For PFS: stage III, N2 and stage (I and II vs III and IV) were significant in univariate analysis, and neoadjuvant chemotherapy and N3 were significant in multivariate analysis.

**Discussion:**
Nasopharyngeal carcinoma is the predominant tumor type arising in the nasopharynx, it differs from other head and neck squamous cell carcinoma and requires particular attention.

The incidence of this carcinoma shows a clear geographical variation and suggests a multifactorial etiology. It is mainly associated with an interaction of several factors; such us Epstein-Barr virus (EBV) infection, the high intake of preserved smoked foods, and genetic predisposition [1].

In most low-risk regions, the disease incidence increase with age; while in high incidence areas, there is a bimodal distribution noted with a minor peak observed among adolescents and young adults and a larger later peak around 50 to 59 years of age and declines thereafter [2]. Median age in our population was 42.95 ± 16.36 years which is compared to the other parts of intermediate-risk regions of North Africa. The incidence of nasopharyngeal carcinoma is two to threefold higher in males compared with females [3]. the sex ratio found in our series was 2.6.

Diagnosis of NPC is often delayed until it manifests by spreading to surrounding structures. Common symptoms reported are headache, nasal obstruction, ear symptoms, and neck swellings [1]. Cranial nerves III, IV, V, and VI are most commonly affected because of para cavernous sinus tumor invasion [9]. Our cases reported neck swellings (61.4%), ear symptoms (52.5%), nasal symptoms (48.5%), and cranial involvement (37.6%).

NPC has a tendency to show early lymphatic and hematogenous spread [10-12]. Lymph node metastases at presentation are present in 75 to 90% of cases and are bilateral in more than 50 percent. In our study we found neck lymph node metastases as the first presenting symptoms in 80.1% of cases.

The World Health Organization (WHO) classifies nasopharyngeal carcinoma into the three histopathologic types [13]. Non keratinizing undifferentiated carcinoma (WHO type III) is the commonly subtype; which is strongly associated with EBV and has a more favorable prognosis than other two subtypes. In our series, we found majority of cases (93%) being undifferentiated subtype III carcinomas.

NPC has mainly treated with radiation therapy (RT) because it is a radiosensitive tumor and because its anatomic location limits a surgical approach. Due to both loco regional control and survival benefit, concurrent chemo radiotherapy has emerged as the standard of care at least for locally advanced stages of nasopharyngeal cancer since the report of the Intergroup 0099 trial in 1998 by Al-Sarraf et al [14], and the confirmation of their results by several subsequent randomized trials and meta analyses [15-20]. Besides, the main advantage of neoadjuvant chemotherapy is early eradication of micro-metastasis, which consequently improves OS by reducing the distant metastasis rate.

Cisplatin is the most effective agent in this setting. However, carboplatin has a more favorable toxicity profile than cisplatin and appears to have similar efficacy [21]. In our cases carboplatin was used in less than 15% of the concurrent chemo radiotherapy due to low glomerular filtration rates. The current standard regimen for concurrent cisplatin is either 100 mg/m2 on days 1, 22, and 43 or a weekly dose of 30 to 40 mg/m2. Weekly schedule was administered for all our patients because it can be given more readily in ambulatory.

However, IMRT can improve target volume coverage and sparing of organs at risk, resulting in excellent dosimetric advantages compared to other radiation techniques in nasopharyngeal cancer [22-24], which theoretically should
lead to reduced late toxicity, especially in terms of xerostomia by sparing dose to one or both parotid glands and improved outcomes [8, 25, 26].

In the present study we show encouraging relapse free survival local control (5-year RFS 76.8%) and overall survival (5-year OS 84.8%) with acceptable acute and limited late toxicities (grade 3 xerostomia: 16.8%) using VMAT combining neoadjuvant chemotherapy, concurrent chemotherapy or both. Furthermore, our results are in good harmony with other IMRT-series [2T-33] describing similar results regarding outcome and toxicity. However, more careful patient selection for sparing of one or both parotid glands seems required and should be weighed against target coverage as highlighted by serious reports on intraparotideal recurrences [34].

**Table 1:** Characteristics of the population.

| Characteristics        | Number | Percentage |
|------------------------|--------|------------|
| Gender                 |        |            |
| Man                    | 73     | 72.3%      |
| Women                  | 28     | 27.7%      |
| Age                    |        |            |
| Average                | 42.95+ / _16.36 |          |
| Diagnosis delay        |        |            |
| Median                 | 6 (4-12) |          |
| Clinical               |        |            |
| Rhinologic syndrome    | 49     | 48.5%      |
| Neck lymph node        | 62     | 61.4%      |
| Otologic syndrome      | 53     | 52.5%      |
| Neurologic syndrome    | 38     | 3.7%       |
| Histology              |        |            |
| SCC moderately differentiated | 3  | 3%      |
| SCC low differentiated  | 4      | 4%         |
| UCNT                   | 94     | 93%        |
| T                      |        |            |
| T1                     | 13     | 12.9%      |
| T2                     | 32     | 31.7%      |
| T3                     | 19     | 18.8%      |
| T4                     | 37     | 36.6%      |
| N                      |        |            |
| N0                     | 12     | 11.9%      |
| N1                     | 23     | 22.8%      |
| N2                     | 56     | 55.4%      |
| N3                     | 10     | 9.9%       |
| STADE                  |        |            |
| I                      | 1      | 1%         |
| II                     | 11     | 10.9%      |
| III                    | 46     | 45.5%      |
| IVA                    | 33     | 32.7%      |
| IVB                    | 10     | 9.9%       |
| Therapeutic protocol   |        |            |
| NEO CMT + RTH          | 8      | 8%         |
| NEO CMT + RCC          | 80     | 79.2%      |
| RCC                    | 13     | 12.8%      |
| EXCLUSIVE RT           | 0      | 0%         |

SCC: Squamous cell carcinoma
UCNT: Undifferentiated carcinoma of nasopharyngeal type
NEO CMT: neoadjuvant chemotherapy
RTH: radiotherapy
RCC: concurrent chemoradiotherapy

**Table 2:** Late complication.

| Late complication | Nombres | Percentage |
|-------------------|---------|------------|
| Fibrosis          | 13      | 12.9%      |
| Lockjaw           | 7       | 6.9%       |
| Hyposialia        | Grade 3 | 20         | 19.8%      |
|                   | Grade 4 | 2          | 2%         |
| Radionecrosis     | Bone    | 0          | 0%         |
|                   | Brain   | 0          | 0%         |
### Table 3: Follow up.

|                      | Value               |
|----------------------|---------------------|
| Following time       | 45.37 ± 17.31       |
| Lost from seen       | 3 (3%)              |
| Time to relapse      | 43.86 ± 18.02       |
| Relapse              | 21 (20.8%)          |
| Relapse seat         |                     |
| Locoregional         | 5 (5%)              |
| Distant              | 16 (15.8%)          |
| Survival             |                     |
| OS                   | OS at 2 years: 98.8%|
|                      | OS at 5 years: 84.8%|
| PFS                  | PFS at 2 years: 85.6%|
|                      | PFS at 5 years: 76.8%|

OS: overall survival  
PFS: relapse free survival

### Table 4: Univariate analysis of OS and PFS.

| Variables               | OS P Value | 95% IC | PFS P Value | 95% IC |
|-------------------------|------------|--------|-------------|--------|
| AGE                     | 0.261      | -      | 0.233       | -      |
| Gender                  | 1.000      | -      | 0.587       | -      |
| Diagnostic delay        | 0.512      | -      | 0.375       | -      |
| Protocol                | 0.887      | -      | -           | -      |
| Induction chemotherapy  | 0.495      | -      | 0.229       | -      |
| Staging                 | 0.737      | -      | -           | -      |
| Stage                   | 0.998      | -      | 0.437       | -      |
| T                       | 0.726      | -      | 0.459       | -      |
| N                       | 0.765      | -      | 0.120       | -      |
| Relapse delay           | <0.001     | 1.07-1.24 | -        | -      |
| Relapse before 2 years  | <0.001     | 12.12-276.84 | -    | -      |
| Stage III               | 0.710      | -      | 0.054       | 0.97-17.31 |
| N2                      | 0.398      | -      | 0.037       | 1.11-35.99 |
| Stage I, II vs Stage III, IV | -    | -      | 0.032       | 0.173-0.923 |

### Table 5: Multivariate analysis of OS.

| Variables               | P Value | 95% C. I Lower | 95% C. I Upper |
|-------------------------|---------|---------------|---------------|
| Relapse delay           | 0.004   | 1.062         | 1.377         |
| Induction chemotherapy  | 0.116   | -             | -             |
| LR relapse vs distant relapse | 0.091 | -             | -             |
| N0                      | 0.193   | -             | -             |
| N1                      | 0.118   | -             | -             |
| N2                      | 0.529   | -             | -             |
| N3                      | 0.042   | 0.002         | 0.901         |

LR: locoregional

### Table 6: Multivariate analysis of PFS.

| Variables               | P Value | 95% C. I Lower | 95% C. I Upper |
|-------------------------|---------|---------------|---------------|
| Stage I, II vs Stage II, IV | 0.999 | -             | -             |
| Induction chemotherapy  | 0.030   | 0.044         | 0.855         |
| N0                      | 0.262   | -             | -             |
| N1                      | 0.190   | -             | -             |
Fig 1: Overall survival (OS) curve.

Fig 2: Progression free Survival (PFS) curve.

|     | N2  | N3  |
|-----|-----|-----|
| OS  | 0.157 | -   | -   |
| PFS | 0.055 | 0.968 | 17.506 |
Fig 3: Survival curve by stage.

Fig 4: Localized Stage vs Locally Advanced Stage Survival.
Conclusion:
IMRT according to the VMAT technique with concurrent chemo radiotherapy with or without additional neoadjuvant chemotherapy has good response and outcomes with acceptable rates of acute and limited rates of late toxicity in patients with nasopharyngeal cancer. Our findings are in good accordance with other series but further large studies are warranted to improve prognostic of this potentially curable malignancy.

Abbreviations list:
NPC: Nasopharyngeal carcinoma
EBV: Epstein Barr virus
AC: adjuvant chemotherapy
RT: radiotherapy
OS: overall survival
PFS: relapse free survival
IMRT: intensity modulated radiotherapy
VMAT: volumetric modulated arc therapy
AJCC: American Joint Committee on Cancer
GTV: gross tumor volume
NP: nasopharyngeal
HR: high-risk
IR: intermediate risk
LR: risk
SCC: Squamous cell carcinoma
UCNT: Undifferentiated carcinoma of nasopharyngeal type
NEO CMT: neoadjuvant chemotherapy
RCC: concurrent chemoradiotherapy

Ethics approval and consent to participate:
Informed consent (verbal) was obtained from all participants. This study was submitted to and approved by research and ethics committee of military teaching hospital Mohamed V

Competing interests:
We (authors) declare that we have no conflict of interest.

Authors' Contribution:
K.H and M.H, performed research and share the first position in this manuscript; A.M and EM analyzed data statistically and drafted the manuscript; M.H and M.B., collected the clinical data; M.E, K.A, K.H, H.S, N.Z and H.M, designed and coordinated research and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgement:
All the authors are thankful for providing the necessary facilities for the preparation the manuscript. Special thanks are due to the Faculty of Medicine and Pharmacy of Rabat; the source(s) of funding for all authors.

Reference:
1. Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet 2016; 387:1012.
2. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1765–77.
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
4. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and Genetics of Head and Neck Tumours. In: World Health Organization Classification of Tumors, IARC Press, Lyon 2005.
5. Zhang L, Zhao C, Ghimire B, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials. BMC Canc. 2010;10:558.
6. Adelstein D, Gillison ML, Pfister DG, et al. NCCN guidelines insights: head and neck cancers, version 2.2017. J NatlComprCancNetw. 2017;15(6):761–770. doi:10.6004/jnccn.2017.0101

7. Chua DTT, Ma J, Sham JST, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol Of J Am SocI Clin Oncol. 2005;23(6):1118–1124. doi:10.1200/ JCO.2005.12.081

8. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006;66(4):981–91.

9. Aiken RD. Neurologic complications of head and neck cancers. Semin Oncol 2006; 33:348.

10. Hsu MM, Tu SM. Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 1983; 52:362.

11. Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet 1997; 350:1087.

12. Altun M, Fandi A, Dupuis O, et al. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995; 32:859.

13. Pathology and genetics of head and neck tumors. In: World Health Organization Classification of Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D (Eds), IARC Press, Lyon 2005.

14. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16:1310–1317.

15. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, Tan HSK, Lee KS, Loong S, Sethi V, Chua EJ, Machin D: Randomized trial of radiotherapy vs concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American joint committee on cancer/international union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005, 23:6730–6738.

16. Lee AW, Lau WH, Tung S, Chua DT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Shams JS, Ngan RK, Law SC, Yau TK, Au JS, O’Sullivan B, Pang ES OSK, Au GK, Lau JT: Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong nasopharyngeal cancer study group. J Clin Oncol 2005, 23:6966–6975.

17. Chan AT, Teo PM, Ngan RK: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002, 20:2038–2044.

18. Lin JC, Jan JS, Hsu C, Liang WM, Jiang RS, Wang WY: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall survival and progression-free survival. J Clin Oncol 2003, 21:631–637.

19. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, Wu PM, Law MW, Kwok CC, Yau CC, Wan KY, Chan RT, Choy DD: Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004, 22:2643–2653.

20. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, Leung SF, Thephemongkol K, Pignon JP: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006, 64:47–56.

21. Chitapanarux I, Lorvidhaya V, Kamersudaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer 2007; 43:1399.

22. Kam MK, Chau RM, Suen J, Choi PH, Teo PM: Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys 2003, 56:145–157.

23. Xia P, Fu KK, Wong GW, Akazawa C, Verhey LJ: Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2000, 48:329–337.

24. Kristensen CA, Kjaer-Kristoffersen F, Sapru W, Berthelsen AK, Loft A, Specht L: Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy. Acta Oncol 2007, 46:214–220.

25. Münter MW, Karger CP, Hoffner G, Hof H, Thilman C, Rudat V, Nill S, Wannenmacher M, Debus J: Evaluation of salivary gland function aftertreatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetatescintigraphy. Int J Radiat Oncol Biol Phys 2004, 58:175–184.

26. Münter MW, Hoffner S, Hof H, Herfarth KK, Haberkorn U, Rudat V, Huber PE, Debus J, Karger CP: Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative
Pertechnetatescintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. Int J Radiat Oncol Biol Phys 2007, 67:651–659.

27. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ: Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006, 64:57–62.

28. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P.

29. Weinberg V, Fu KK: Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the USCF experience. Int J Radiat Oncol Biol Phys 2002, 53:12–22.

30. Kwong DL, Sham JS, Leung LH, Cheng AC, Kwong PW, Lui WM, Yau CC, Wu PM, Wei W, Au G: Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 64:374–381.

31. Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, Leung SF, Zee B, Chan AT: Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2009, 75:1481–1486.

32. Tham IW, Hee SW, Yeo RM, Salleh PB, Lee J, Tan TW, Fong KW, Chua ET, Wee JT: Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy – the national cancer center Singapore experience. Int J Radiat Oncol Biol Phys 2009, 75:1481–1486.

33. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Kian Ang K: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009, 27:3684–3690.

34. Peponi E, Glanzmann C, Kunz G, Renner C, Tomuschat K, Studer G.

35. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) in nasopharyngeal cancer. Strahlenther Onkol 2010, 186:135–142.

36. Cannon DM, Lee NY: Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008, 70:660–665.